NCT03156439View on ClinicalTrials.gov

Bioavailability, Safety, and Tolerability of BIS-001 ER

PHASE1CompletedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

May 22, 2017

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions

Epilepsy, Complex Partial

Interventions

DRUG

BIS-001 ER

BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.

Trial Locations (1)

3050

The Royal Melbourne Hospital, Parkville

Sponsors

Collaborators (1)

Melbourne Health

All Listed Sponsors

collaborator

Melbourne Health

OTHER

lead

Supernus Pharmaceuticals, Inc.

INDUSTRY

NCT03156439 - Bioavailability, Safety, and Tolerability of BIS-001 ER | Biotech Hunter | Biotech Hunter